CN108358999A - A kind of estrogen receptor targeting peptides and its preparation and application - Google Patents
A kind of estrogen receptor targeting peptides and its preparation and application Download PDFInfo
- Publication number
- CN108358999A CN108358999A CN201810043625.4A CN201810043625A CN108358999A CN 108358999 A CN108358999 A CN 108358999A CN 201810043625 A CN201810043625 A CN 201810043625A CN 108358999 A CN108358999 A CN 108358999A
- Authority
- CN
- China
- Prior art keywords
- seq
- targeting peptides
- estrogen receptor
- receptor alpha
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 63
- 230000008685 targeting Effects 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 102000015694 estrogen receptors Human genes 0.000 title description 4
- 108010038795 estrogen receptors Proteins 0.000 title description 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims abstract description 31
- 102100038595 Estrogen receptor Human genes 0.000 claims abstract description 31
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 22
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 239000002773 nucleotide Substances 0.000 claims abstract description 10
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 10
- 239000003560 cancer drug Substances 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 239000013612 plasmid Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000010276 construction Methods 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 239000000969 carrier Substances 0.000 claims description 12
- 230000029087 digestion Effects 0.000 claims description 12
- 230000002441 reversible effect Effects 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 239000013613 expression plasmid Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000002474 experimental method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 238000011534 incubation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000035519 G0 Phase Effects 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 238000010583 slow cooling Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- ZFADFBPRMSBPOT-KKUMJFAQSA-N Gln-Arg-Phe Chemical compound N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZFADFBPRMSBPOT-KKUMJFAQSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- LBCAQRFTWMMWRR-CIUDSAMLSA-N His-Cys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O LBCAQRFTWMMWRR-CIUDSAMLSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 2
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 230000006674 lysosomal degradation Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- -1 9-fluorenylmethyloxycarbonyl protecting group Chemical group 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- OBFTYSPXDRROQO-SRVKXCTJSA-N Arg-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCN=C(N)N OBFTYSPXDRROQO-SRVKXCTJSA-N 0.000 description 1
- XUGATJVGQUGQKY-ULQDDVLXSA-N Arg-Lys-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XUGATJVGQUGQKY-ULQDDVLXSA-N 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 1
- QOOFKCCZZWTCEP-AVGNSLFASA-N Glu-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O QOOFKCCZZWTCEP-AVGNSLFASA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 1
- ZJSZPXISKMDJKQ-JYJNAYRXSA-N Lys-Phe-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 ZJSZPXISKMDJKQ-JYJNAYRXSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- JWQWPTLEOFNCGX-AVGNSLFASA-N Phe-Glu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWQWPTLEOFNCGX-AVGNSLFASA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- WBINSDOPZHQPPM-AVGNSLFASA-N Ser-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)O WBINSDOPZHQPPM-AVGNSLFASA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 150000004075 acetic anhydrides Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a kind of estrogen receptor alpha targeting peptides, wherein the targeting peptides have such as SEQ ID No:Amino acid sequence shown in 1, the nucleotide sequence such as SEQ ID No of encoding gene:In 4 34~120 shown in;Application the present invention also provides the preparation method of the estrogen receptor alpha targeting peptides and its in preparing estrogen receptor alpha positive breast cancer drug.
Description
Technical field
The present invention relates to a kind of polypeptide for treating tumour and preparation method and applications, more particularly to a kind of and estrogen
Polypeptide of receptor alpha specific binding and preparation method thereof and its answering in preparing estrogen receptor alpha positive breast cancer drug
With.
Background technology
In global female cancer, pathogenesis of breast carcinoma number and death toll are all located at front two, and incidence by
Year rises, and is the primary killers for endangering women's health.About 70% patient with breast cancer due to estrogen receptor alpha (ER α) be overexpressed,
It is clinically ER α positive breast cancers by parting.There is tamoxifen for the targeted drug master of ER α shot designs at present
(TAM), fulvestrant (FUL) and arimedex (AI), but ER α breast cancer patients with positive receives these targeted drugs
After treating a period of time, different degrees of drug resistance will produce.
In the prior art, the therapy for ER α positive breast cancers further includes immunotherapy and gene therapy,
In CN201710110542.8, using CDK4/6 inhibitor and estrogen receptor antagon combination therapy breast cancer, but to immune
The long-term inhibition of system be easy to cause liver renal toxicity and embryo's defect etc.;However, current gene therapy although achieve it is considerable
Progress, but still will produce some serious adverse reactions over the course for the treatment of simultaneously, as haemocyte is reduced, heart failure and
Embryo's defect etc..
Invention content
Goal of the invention:The first object of the present invention is to provide a kind of polypeptide with estrogen receptor alpha specific binding;This
Second purpose of invention is to provide the preparation method of this polypeptide;The third object of the present invention is to provide this polypeptide and is preparing
Application in estrogen receptor alpha positive breast cancer drug.
Technical solution:Estrogen receptor alpha targeting peptides of the present invention, i.e. I-CTM of α have such as SEQ ID No:Shown in 1
Amino acid sequence, specially:Lys1Phe2Glu3Arg4Gln5Lys6Ile7Leu8Asp9Gln10Arg11Phe12Phe13Glu14Se
r15Ser16Glu17Tyr18Cys19Phe20Tyr21Trp22Asp23Ser 24Ala25His26Cys27Ser28Arg29;Its encoding gene
Nucleotide sequence such as SEQ ID No:In 4 34~120 shown in.
Wherein, the targeting peptides also have such as SEQ ID No:Amino acid sequence shown in 2, i.e. TAT, specially:
Tyr1Gly2Arg3Lys4Lys5Arg6Arg7Gln8Arg9Arg10Arg11;The nucleotide sequence of its encoding gene such as SEQ ID
No:In 4 1~33 shown in.
Preferably, by SEQ ID No:Nucleotide sequence shown in 4 is cloned at the multiple cloning sites of expression plasmid, i.e.,
The amino acid sequence SEQ ID No of the targeting peptides:2 and amino acid sequence SEQ ID No:1 is directly connected by a peptide bond
It connects, the targeting peptides, i.e. I-CTM's of TAT- α, amino acid sequence such as SEQ ID No:Shown in 3, specially:
Tyr1Gly2Arg3Lys4Lys5Arg6Arg7Gln8Arg9Arg10Arg11Lys12Phe13Glu14Arg15Gln16Lys17Il
e18Leu19Asp20Gln21Arg22Phe23Phe24Glu25Ser26Ser27Glu28Tyr29Cys30Phe31Tyr32Trp33As
p34Ser35Ala36His37Cys38Ser39Arg40。
The expression vector of the encoding gene of the estrogen receptor alpha targeting peptides, it includes above-mentioned nucleotide sequence SEQ
ID No:4.
The host cell of the encoding gene of the estrogen receptor alpha targeting peptides expresses above-mentioned estrogen receptor alpha targeting
Peptide.
It is described that there is amino acid sequence SEQ ID No:1 and SEQ ID No:The preparation of 2 estrogen receptor alpha targeting peptides
Method includes the following steps:
(1) plasmid construction in first structure domain:Synthesize two mononucleotide chains in first structure domain, wherein positive sequence
Such as SEQ ID No:5 shown, reverse sequence such as SEQ ID No:Shown in 6, then with specific b amHI and EcoRI double digestion
PET-22b carriers are attached reaction, obtain pET-22b-A carriers (i.e. pET-22b-TAT plasmids);
The plasmid construction of (2) second structural domains:Synthesize two mononucleotide chains of the second structural domain, wherein positive sequence
Such as SEQ ID No:7 shown, reverse sequence such as SEQ ID No:Shown in 8, then with the specific SalI obtained in step (1) and
The pET-22b-A carriers of NotI double digestions are attached reaction, obtain pET-22b-A-B carriers (i.e. pET-22b-TAT-CTM
Plasmid);
(3) plasmid construction of third structural domain:Synthesize two mononucleotide chains of third structural domain, wherein positive sequence
Such as SEQ ID No:9 shown, reverse sequence such as SEQ ID No:Shown in 10, then with the specific SalI obtained in step (1) and
The pET-22b-A-B carriers of NotI double digestions are attached reaction, obtain pET-22b-A-B-C plasmids (i.e. pET-22b-TAT-
α I-CTM plasmids);
(4) the pET-22b-A-B-C plasmids obtained in step (3) are transferred to competent E.coli DH5 α, extract matter
Grain is simultaneously sequenced;
(5) the correct plasmid of sequencing in step (4) is transferred to competent E.coli DE3, progress protein expression is simultaneously pure
Change, obtains the estrogen receptor alpha targeting peptides.
With amino acid sequence SEQ ID No:1 or have SEQ ID No:1 and 2 estrogen receptor alpha targeting peptides are being made
Application in standby estrogen receptor alpha positive breast cancer drug.
Advantageous effect:Compared with prior art, the present invention its remarkable advantage is:Small peptide α I can directly be acted on simultaneously with ER α
And it specifically binds;The ER α targeting peptides α I-CTM synthesized in vitro can target that so that intracellular ER α albumen is passed through CMA approach molten
Enzyme body is degraded;To influence vigor and the period of cell, the MCF-7 cell viabilities of α I-CTM-RFP are transferred to than being transferred to CTM-
RFP's has dropped 6.1%, also results in the cell G0/G1 phases and blocks;Meanwhile the ER α targeting peptides TAT- α I-CTM synthesized in vitro
ER α protein levels in cell can not only be reduced, and with the increase of targeting peptides dosage, the proliferation of MCF-7 Breast Cancer Cell
Significantly inhibited, cell viability declines about 24.3%.It is provided newly to prepare estrogen receptor alpha positive breast cancer drug
Approach.
Description of the drawings
Figure 1A is the Western Bloting for the GST pull-down experiments that α I are combined with ER alpha specifics in 293T cells
Result figure;
Figure 1B is the Western for the GST pull-down experiments that α I are combined with ER alpha specifics in MCF-7 and T47D cells
Bloting result figures;
Fig. 2A is ER α protein expression levels in ER α targeting peptides α I-CTM degradation ER α positive breast cancer cells MCF-7
Western Bloting result figures;
Fig. 2 B are the real-time PCR knots that ER α targeting peptides α I-CTM influence the mRNA level in-site of ER α in MCF-7 cells
Fruit is schemed;
Fig. 3 A are experimental result pictures of the flow cytomery ER α targeting peptides α I-CTM to MCF-7 Cell cycle influences;
Fig. 3 B are the influence result figure that CCK8 kits detect that ER α targeting peptides α I-CTM inhibit MCF-7 cell Proliferations;
Fig. 4 A are targeting peptides TAT- α I-CTM to ER α protein expression levels in ER α positive breast cancer cells MCF-7
Western Bloting result figures;
Fig. 4 B are the influence result that CCK8 kits detection synthesis targeting peptides TAT- α I-CTM inhibit MCF-7 cell Proliferations
Figure;
Fig. 5 is the high performance liquid chromatography and Mass Spectrometer Method result figure of the ER α targeting peptides TAT- α I-CTM of synthesis.
Specific implementation mode
Technical scheme of the present invention is further described below in conjunction with drawings and examples.
Biomaterial, carrier, bacterial strain, reagent and kit etc. used in the present invention can be bought by routine business and be obtained
, the biological gene engineering operating technology being directed to, such as plasmid extraction, digestions, segment recycling, nucleic acid fragment and matter
Grain carrier connection reaction and clone and screening etc., be routine operation in the art or with reference to corresponding commodity specification into
Row operation.
Biomaterial, carrier, the source of bacterial strain or model used in the present invention are as follows:
293T cells be 293T (CRL-3216TM);
MCF-7 cells be MCF-7 (HTB-22TM);
T47D cells be T47D (HTB-133TM);
DH5 α and BL21 (DE3) bacterial strain is purchased from Shanghai Wei Di Bioisystech Co., Ltd;
PEGFP-N2, pET-22b and pGEX-6P-1 plasmid are purchased from biological wind website:www.biofeng.com;
BamHI-HF, EcoRI-HF, SalI-HF and NotI-HF enzyme are purchased from New England Biolabs;
Biology, chemical reagent source used in the present invention are as shown in table 1:
1 biology of table, chemical reagent source
The primer of the present invention is as shown in table 2:
2 Primer of table and its nucleotide sequence
Embodiment 1:The chemical synthesis of estrogen receptor alpha targeting peptides
It weighs 1g resins to be put into reactor, DCM is added and is swollen half an hour, then takes out DCM, 1mmol in sequence is added
First amino acid L-type glutamic acid of equivalent, the DIC of 1mmol;The DMAP of 1mmol, suitable DMF solution are bubbled anti-with nitrogen
Answer 3h;Then 1ml pyridines are added, 1ml acetic anhydrides react half an hour, take out reaction solution, are cleaned with DMF, DCM.It is added appropriate
Piperidines removes 9-fluorenylmethyloxycarbonyl protecting group, cleans, ninhydrin detection;Second ammonia of 3mmol in sequence is added into reactor
Base acid, 3mmol HOBT and DIC, nitrogen blistering reaction one hour take out liquid, are cleaned with DMF, ninhydrin detection.According to step
Rapid aforesaid way sequentially adds amino acid in sequence, until the reaction of last L-type tyrosine terminates.Add a certain amount of 95% trifluoro
Acetic acid cutting liquid, concussion reaction 2h, it is therefore an objective to the side chain protecting group of amino acid be cleaved, thick peptide prod is obtained.Analysis
Purification and Mass Spectrometer Method:The correctness that the acid molecules amount is detected with ESI-MS mass spectrographs is carried thick peptide with high performance liquid chromatography
It is pure to 95% it is pure more than, take off tfa salt, the estrogen receptor alpha targeting peptides pET-22b-TAT- α I-CTM purified.
Embodiment 2:The biosynthesis of estrogen receptor alpha targeting peptides
1, plasmid construction
First, the plasmid construction of first structure domain pET-22b-TAT:Two mononucleotide chains of synthetic primer TAT, sequence
HindIII and KpnI restriction enzyme sites are added in row, the positive sequence that BamHI and EcoRI cohesive ends are contained at sequence both ends is
SEQ ID No:5, HindIII and KpnI restriction enzyme sites are added in sequence, BamHI and EcoRI cohesive ends are contained at sequence both ends
Reverse sequence be SEQ ID No:6.By mononucleotide chain annealing reaction, 50 μ L reaction systems include 5 μ g forward direction monokaryon glycosides
Sour chain, the reversed mononucleotide chains of 5 μ g, 5 μ L NEB buffer 2.Reagent is evenly mixed in EP pipes anti-by following conditions
It answers, 95 DEG C, 5 minutes;70 DEG C, 10 minutes;Slow cooling is to room temperature.Take 8 μ L reaction products, with 50ng specific bs amHI and
EcoRI double digestion pET-22b carriers are attached reaction, obtain pET-22b-TAT.
Secondly, the plasmid construction of the second structural domain pET-22b-TAT-CTM:Two mononucleotides of synthetic primer CTM
Chain, the positive sequence containing SalI and NotI cohesive ends is SEQ ID No in primer:7, contain SalI and NotI viscosity end
The reverse sequence at end is SEQ ID No:8.By mononucleotide chain annealing reaction, 50 μ L reaction systems include 5 μ g forward direction monokaryons
Thuja acid chain, the reversed mononucleotide chains of 5 μ g, 5 μ L NEB buffer 2.Reagent is evenly mixed in EP pipes anti-by following conditions
It answers, 95 DEG C, 5 minutes;70 DEG C, 10 minutes;Slow cooling is to room temperature.Take 8 μ L reaction products, with 50ng specificity SalI and
NotI double digestion pET-22b-TAT carriers are attached reaction, obtain pET-22b-TAT-CTM.
Finally, the plasmid construction of third structural domain pET-22b-TAT- α I-CTM:Two mononucleotides of synthetic primer α I
Chain, the positive sequence containing KpnI and EcoRI cohesive ends is SEQ ID No in primer:9, contain KpnI and EcoRI viscosity
The reverse sequence of end is SEQ ID No:10.By mononucleotide chain annealing reaction, 50 μ L reaction systems include 5 μ g positive
Mononucleotide chain, the reversed mononucleotide chains of 5 μ g, 5 μ L NEB buffer 2.Reagent is evenly mixed in EP pipes by following
Part reacts, 95 DEG C, 5 minutes;70 DEG C, 10 minutes;Slow cooling is to room temperature.8 μ L reaction products are taken, with 50ng specificity KpnI
It is attached reaction with EcoRI double digestion pET-22b-TAT-CTM carriers, obtains pET-22b-TAT- α I-CTM plasmids, it will
Obtained plasmid is transferred to competent E.coli DH5 α, shakes bacterium extraction plasmid and is sequenced;.
2, expression and purification target protein
The prokaryotic expression plasmid built is transformed into protein expression Escherichia coli DE3 competent cells.First picking list
Bacterium colony is placed in the triangular pyramidal bottle of the LB culture mediums containing kanamycins and is cultivated in a small amount overnight.Press 1 within second day:200 ratios
Example, which is drawn to be incubated overnight bacterium solution and be added in the LB culture mediums containing kanamycins, is enlarged culture, and 37 DEG C are cultivated to OD values
Up to 0.6, the IPTG that final concentration of 0.1mM is added carries out protein induced expression, and inducing temperature is 18 DEG C of overnight incubations.By from
The heart collects the bacterium of induced expression overnight, with protein cleavage (50mM Tris, pH 7.5, the 100mM NaCl, 1mM of precooling
EDTA, 1Mm EGTA, 1% NP-40) bacterial precipitation is resuspended.1 is pressed into the thalline of resuspension:100 ratios are added protease and inhibit
After being incubated 30 minutes on ice, ultrasonication is carried out using cell Ultrasonic Cell Disruptor for agent PMSF and lysozyme.After ultrasound,
10000g, 4 DEG C of high speed centrifugations 30 minutes.After centrifugation, supernatant and PBS is taken to wash Glutathione SepHarose three times
Beads carries out 4 DEG C of rotations and is incubated 4 hours.After incubation, pours the mixture into protein purification column and purified.Use wash
Buffer A (50mM Tris, pH 7.5,100mM NaCl, 1 mM EDTA, 1Mm EGTA, 1mM DTT) are flushed three times, then are used
Wash buffer B (50mM Tris, pH 7.5,100mM NaCl, 1mM DTT) are flushed three times, and finally use release
buffer(50mM Tris, pH 7.5,150mM NaCl,1mM DTT,and 20mM reduced glutathione,pH
7.5) albumen, the estrogen receptor alpha targeting peptides purified, high performance liquid chromatography and Mass Spectrometer Method result figure such as Fig. 5 are eluted
It is shown.
Embodiment 3:Verify α I small peptides specific binding ER α
GST Pull-down experiments:By the gst fusion protein of the GST zero loads albumen after purification of 5 μ g and 5 μ g respectively with
The 30 μ L Glutathione SepHarose beads incubations at room temperature of 500 μ l PBS pre-wash three times combine 1 hour.It incubates
After educating, flushed three times with 500 μ l PBS.Two disk of cell that 100mm culture dishes cover with is taken, is scraped and is collected with cell scraper
Cell is added RIPA lysates (inhibition of 10 μ l protease has been added) lytic cell of 1ml precoolings, collects cell pyrolysis liquid, take
100 μ l supernatants are divided into two equal portions as Input groups, by remaining cell pyrolysis liquid.Respectively be combined with GST zero loads albumen and
4 DEG C of rotations of beads of gst fusion protein are incubated overnight.After incubation, supernatant 1ml wash buffer (50mM are abandoned
Tris, pH 7.5,150mM NaCl, 1mM EDTA, 1mM DTT, 0.1%Nonidet P-40) it washs 3 times, 4 DEG C of rotations every time
Turn 5min.Beads is collected, 50 μ L Release Buffe elutions are added.It is proportionally added into 20 μ 5 × Loading of l Buffer.
95 DEG C of heating 10min are detected result by Western Blotting experiments.
Western Bloting experiments:100mm culture dish cells are collected, the 1ml RIPA cracking being pre-chilled is added
Liquid (inhibition of 10 μ l protease has been added) lytic cell, collects cell pyrolysis liquid and carries out albumen concentration quantitative, after quantifying in proportion
It is added 5 × loading buffer, 95 DEG C are boiled the protein sample of 10 μ l is taken to be loaded in SDS-PAGE glue after ten minutes, are carried out
Electrophoresis, then transferring film.After transferring film, takes out pvdf membrane and closed with the skim milk of 50ml 5%.It is cut after closing
Purpose band is taken, is put into the centrifuge tube containing 8ml primary antibody buffer solutions, the antibody in centrifuge tube is that 8 μ l GST antibody (are purchased from
CST, number 2624,1:1000 dilution), 8 μ l ER Alpha antibodies (be purchased from CST, number 8644,1:1000 dilutions) and 0.8 μ l β-
Actin antibody (is purchased from Proteintech, number 60008-1-Ig, 1:10000 dilutions).4 DEG C are jiggled overnight, rear to use
TBST buffer solutions wash 5 times, every time 5 minutes.Be added couple horseradish peroxidase secondary antibody horseradish peroxidase couple it is anti-
Mouse IgG and anti-rabbit IgG (being purchased from Santa Cruz Biotechnology), antibody is diluted to specifications, secondary antibody and film
Incubation at room temperature 1 hour is washed 5 times, every time 5 minutes after secondary antibody is incubated with TBST buffer solutions.It takes out film and developer solution is added,
Albumen variation is detected by imaging of biomolecules instrument analysis system.
Plasmid is overexpressed experiment:The day before transfection takes the cell that logarithmic phase is grown, and is inoculated in 6 orifice plates after digestion, 293T
Cell 1.7 × 106A/per hole, it is placed in serum free medium, 37 DEG C, 5%CO2, it is small that 18 to 20 is cultivated in cell incubator
When, wait for that cell confluency rate reaches 80%-90% and transfected.It (is purchased from according to transfection reagent2000) it says
Bright book prepares DNA- transfection reagent mixtures:
A:200 μ l Opti-MEM+12 μ l Lip2000, mixing are stored at room temperature 5min.
B:200 μ l Opti-MEM+4 μ g plasmids, mixing are stored at room temperature 5min.
According to 1:1 ratio is by room temperature stationary incubation 20min after A and B mixings.Old culture medium in 6 orifice plates is sucked, is added
1.5ml is added without dual anti-culture medium, and by above-mentioned transfection mixture in 6 orifice plates hole.37 DEG C, culture 24 is small under the conditions of 5% CO2
When or 48 hours, collect albumen sample and carry out Western Blotting experiment detection.
Inventor screens a small peptide α I for capableing of specific recognition ER α according to the method for the prior art in document, presses
According to the method in embodiment 2 using pGEX-6P-1 as vector construction GST expression plasmids, using pEGFP-N2 as vector construction ER α tables
Up to plasmid.Expression obtains GST-TAT- α I and GST-TAT- α I-CTM in DE3, then obtains mesh by protein expression and purification
Albumen, carry out external Pull-down experiments, ER α be overexpressed in 293T cells, collect cell after 48 hours, cracking takes
Clearly with after purification GST-TAT- α I fusion proteins and GST reference proteins be incubated overnight, after washing and elution, carry out
Western Bloting experiments;As a result as shown in figure 1;Inventor have chosen ER α positive breast cancer cells MCF-7 and
T47D has carried out external pull-down experiments, as a result as shown in fig. 1b respectively.Attached drawing 1A proves α I with 1B experimental results
Directly it can act on and specifically bind with ER α.
Embodiment 4:Influences of the α I-CTM to ER α albumen in breast cancer cell
RNA extractions, reverse transcription experiment:Using OMEGA Total RNA extracts kits (purchased from Nanjing Rui Jingte biologies
Science and Technology Ltd.), it is operated according to product description.RNA concentration is measured with Nanodrop 2000 after elution, carries out reverse transcription
Reaction.Reverse transcription reaction system:Contain 2500ng RNA, 10 μ L5 × PrimeScript RT in the reaction volume of 50 μ L
Master Mix and distilled water.It is reacted according to the program of following settings in PCR instrument:37 DEG C, 15min;85 DEG C, 5sec.
Real-time PCR experiments:Using reverse transcription product cDNA as template, PCR amplification is carried out with following primer:10μL
Contain 1 μ L cDNA templates in reaction system, 0.2 μ L (10nmol) sequence is SEQ ID No:11 forward primer, 0.2 μ L
(10nmol) sequence is SEQ ID No:12 reverse primer, 5 μ 2 × SYBR of L Mix, 3.6 μ L distilled waters.
CFX96TMReal-Time System fluorescence quantitative PCR instruments react 40 cycles according to the program of following settings:Pre-degeneration, 95
DEG C, 30sec;Denaturation, 95 DEG C, 5sec;Annealing, 60 DEG C, 30sec.
According to the method in embodiment 2 using pEGFP-N2 as vector construction CTM-RFP, α I-CTM-RFP and α I-mCTM-
RFP expression plasmids are overexpressed by plasmid and are tested, be transferred to CTM-RFP, α respectively in ER α positive breast cancer cells MCF-7
I-CTM-RFP and α I-mCTM-RFP.Cell is collected in transfection after 24 hours, extract albumen, is carried out according to the method in embodiment 3
Western Bloting experiment, be added RFP antibody (be purchased from Abcam, number ab62341,1:1000 dilution), ER Alpha antibodies (purchase
From CST, number 8644,1:1000 dilutions) and β-actin antibody (purchased from Proteintech, number 60008-1-Ig, 1:
10000 dilutions);And RNA extractions, reverse transcription experiment and Real-time PCR experiments are carried out according to the method described above and detects ER respectively
The expression quantity of the mRNA of α albumen and ER α.Experimental result is respectively as shown in attached drawing 2A and attached drawing 2B.
The experimental result of Real-time PCR is as shown in table 1:
The mRNA relative expression quantities of ER α in table 1.ER α positive breast cancer cells
Group | CTM-RFP | αI-CTM-RFP | αI-mCTM-RFP |
Mrna expression amount/2- △ △ Ct | 1 | 0.906613 | 0.87069 |
In attached drawing 2A Western Bloting test the results show that in α I-CTM-RFP groups, intracellular ER α albumen
Level will be less than other groups;The experimental result of Real-time PCR is shown in attached drawing 2B, the mRNA level in-site of this group of ER α and other
The no apparent difference of group, above the experimental results showed that:ER α targeting peptides α I-CTM, which can be targeted, makes intracellular ER α albumen pass through
CMA approach is by lysosomal degradation.
Embodiment 5:The influence of α I-CTM cell cycles and vigor
Cell cycle is detected:The cell of logarithmic growth phase is seeded to 6 orifice plates after digestion, waits for that cell confluency rate reaches
80% or so, experiment process is carried out, cell is collected after 24 hours.After PBS is washed twice, 70% ethyl alcohol of -20 DEG C of precoolings is added
It is fixed to stay overnight.Supernatant is abandoned, 300 μ L propidium iodide stains liquid (PI) is added, cell precipitation is resuspended.Room temperature is protected from light incubation dyeing
30min, stream type cell analyzer detect the cell cycle.
Cell viability detects:Single cell suspension is made with 0.25% trypsin digestion in logarithmic growth phase cell, profit
It is counted with blood counting chamber, inoculating cell suspension (100 holes μ L/, 5000 cells) in 96 orifice plates, 37 DEG C, 5%CO2Cell
Overnight incubation in incubator carries out experiment process.Arrive separately at for 24 hours, liquid is changed after 48h, 72h, 100 μ L are added into every hole and contain
The cell culture complete medium of 10 μ L CCK-8 solution, culture plate is put into incubator and is incubated 1.5 hours.It is measured with microplate reader
Light absorption value at (measuring wavelength 450).Light absorption value size reflects cell activity, according to experimental data, using the time as abscissa,
Light absorption value is mapped for ordinate.According to the method in embodiment 2 using pEGFP-N2 as vector construction CTM-RFP, α I-CTM-RFP
With α I-mCTM-RFP expression plasmids, α I-CTM-RFP and CTM-RFP are individually transferred in MCF-7 cells, and with CTM-
RFP as a contrast, is detected its cell cycle after 24 hours, and experimental result is as shown in table 2 and attached drawing 3A;Make simultaneously
With CCK8 kits, detect the influence of its cell proliferation generation according to the specification in kit, experimental result such as table 3 and
Shown in attached drawing 3B:
Influences of the table 2.ER α targeting peptides α I-CTM to the MCF-7 cell cycles
Influences of the table 3.ER α targeting peptides α I-CTM to MCF-7 cell Proliferations
Cell cycle experimental result in attached drawing 3A and table 2 is shown, is transferred to the G0/G1 of the MCF-7 cells of α I-CTM-RFP
Phase extends, and the S phases shorten;Cell viability testing result in attached drawing 3B and table 3 is shown, is transferred to the MCF-7 cells of α I-CTM-RFP
Vigor has dropped 6.1% than be transferred to CTM-RFP, illustrates that the cell Proliferation for being transferred to α I-CTM-RFP is suppressed.The above reality
Test the result shows that, α I-CTM cause intracellular ER α protein levels to reduce vigor and the period that can influence cell, and cell is caused to be lived
Power declines and the cell G0/G1 phases block.
Embodiment 6:Influences of the ER α targeting peptides TAT- α I-CTM of synthesis to ER α protein expression levels in cell
According to the method chemical synthesis estrogen receptor alpha targeting peptides in embodiment 1, by the polypeptide of various dose and ER α sun
Property breast cancer cell MCF-7 be incubated 24 hours, carry out Western Bloting experiments according to the method in embodiment 3,
As a result as shown in fig 4;It uses 1640 complete mediums of 2ml that 200 μ g ER α targeting peptides TAT- α I-CTM are added again, adds after mixing
In six orifice plates for entering positive breast cancer cells MCF-7, using blank group as control group, 200mg/ml ER α targeting peptides are added
TAT- α I-CTM are experimental group.Using CCK8 kits, according to the specification detection ER α targeting peptides TAT- α I- in kit
The influence that CTM cell proliferations generate, as a result as shown in attached drawing 4B and table 4.
Influences of the table 4.ER α targeting peptides TAT- α I-CTM to MCF-7 cell Proliferations
Attached drawing 4A's the results show that with ER α targeting peptides TAT- α I-CTM dosage increase, the amounts of ER α protein degradations by
It is cumulative to add, the experimental results showed that the ER α targeting peptides TAT- α I-CTM of synthesis can reduce ER α protein levels in cell.Attached drawing 4B
And the experimental result of table 4 is shown, MCF-7 cells are after the ER α targeting peptides TAT- α I-CTM that synthesis is added, under cell viability
24.3% has been dropped, has been proliferated by apparent inhibiting effect.
Above example shows:Small peptide α I directly can be acted on and specifically bind with ER α;ER α targeting peptides α I-CTM
Can target makes intracellular ER α albumen pass through CMA approach by lysosomal degradation;To influence vigor and the period of cell, cause
Cell viability declines and the cell G0/G1 phases block;Meanwhile ER α targeting peptides TAT- α I-CTM can not only reduce ER α in cell
Protein level, and with the increase of targeting peptides dosage, the proliferation of MCF-7 Breast Cancer Cell is significantly inhibited.
SEQUENCE LISTING
<110>Nanjing Normal University
<120>A kind of estrogen receptor targeting peptides and its preparation and application
<130> 2017.1.9
<160> 10
<170> PatentIn version 3.3
<210> 1
<211> 29
<212> PRT
<213>It is artificial synthesized
<400> 1
Lys Phe Glu Arg Gln Lys Ile Leu Asp Gln Arg Phe Phe Glu Ser Ser
1 5 10 15
Glu Tyr Cys Phe Tyr Trp Asp Ser Ala His Cys Ser Arg
20 25
<210> 2
<211> 11
<212> PRT
<213>It is artificial synthesized
<400> 2
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10
<210> 3
<211> 40
<212> PRT
<213>It is artificial synthesized
<400> 3
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ser Ser Glu Tyr Cys
1 5 10 15
Phe Tyr Trp Asp Ser Ala His Cys Ser Arg Lys Phe Glu Arg Gln Lys
20 25 30
Ile Leu Asp Gln Arg Phe Phe Glu
35 40
<210> 4
<211> 120
<212> DNA
<213>It is artificial synthesized
<400> 4
tatggcagga agaagcggag acagcgacga agaagcagcg agtactgctt ctactgggac 60
agcgcccact gcagccggaa gtttgagcgt cagaagattc tggaccagag gttctttgag 120
<210> 5
<211> 57
<212> DNA
<213>It is artificial synthesized
<400> 5
gatccgtatg gcaggaagaa gcggagacag cgacgaagaa agcttggtac cccgggg 57
<210> 6
<211> 57
<212> DNA
<213>It is artificial synthesized
<400> 6
aattccccgg ggtaccaagc tttcttcgtc gctgtctccg cttcttcctg ccatacg 57
<210> 7
<211> 49
<212> DNA
<213>It is artificial synthesized
<400> 7
tcgacaagtt tgagcgtcag aagattctgg accagaggtt ctttgaggc 49
<210> 8
<211> 49
<212> DNA
<213>It is artificial synthesized
<400> 8
ggccgcctca aagaacctct ggtccagaat cttctgacgc tcaaacttg 49
<210> 9
<211> 49
<212> DNA
<213>It is artificial synthesized
<400> 9
cagcagcgag tactgcttct actgggacag cgcccactgc agccggggg 49
<210> 10
<211> 57
<212> DNA
<213>It is artificial synthesized
<400> 10
aattcccccg gctgcagtgg gcgctgtccc agtagaagca gtactcgctg ctggtac 57
Claims (7)
1. a kind of estrogen receptor alpha targeting peptides, it is characterised in that:The targeting peptides have such as SEQ ID No:Amino shown in 1
Acid sequence, the nucleotide sequence such as SEQ ID No of encoding gene:In 4 34~120 shown in.
2. estrogen receptor alpha targeting peptides according to claim 1, it is characterised in that:The targeting peptides also have such as SEQ
ID No:Amino acid sequence shown in 2, the nucleotide sequence such as SEQ ID No of encoding gene:In 4 1~33 shown in.
3. the estrogen receptor alpha targeting peptides described in claim 2, it is characterised in that:By SEQ ID No:Nucleotides sequence shown in 4
Row are cloned at the multiple cloning sites of expression plasmid, i.e., the amino acid sequence SEQ ID No of the described targeting peptides:2 with amino acid sequence
Arrange SEQ ID No:1 is directly connected to by a peptide bond.
4. the expression vector of the encoding gene of the estrogen receptor alpha targeting peptides described in claim 1~2, it is characterised in that:It is wrapped
Containing the nucleotide sequence SEQ ID No:4.
5. the host cell of the encoding gene of the estrogen receptor alpha targeting peptides described in claim 1~2, it is characterised in that:Its table
Up to the estrogen receptor alpha targeting peptides.
6. the preparation method of the estrogen receptor alpha targeting peptides described in claim 2, it is characterised in that:Include the following steps:
(1) plasmid construction in first structure domain:Synthesize two mononucleotide chains in first structure domain, wherein positive sequence such as SEQ
ID No:5 shown, reverse sequence such as SEQ ID No:Shown in 6, then the pET-22b loads with specific b amHI and EcoRI double digestion
Body is attached reaction, obtains pET-22b-A carriers;
The plasmid construction of (2) second structural domains:Synthesize two mononucleotide chains of the second structural domain, wherein positive sequence such as SEQ
ID No:7 shown, reverse sequence such as SEQ ID No:Shown in 8, then with the specific SalI and the bis- enzymes of NotI that are obtained in step (1)
The pET-22b-A carriers cut are attached reaction, obtain pET-22b-A-B carriers;
(3) plasmid construction of third structural domain:Synthesize two mononucleotide chains of third structural domain, wherein positive sequence such as SEQ
ID No:9 shown, reverse sequence such as SEQ ID No:Shown in 10, then it is bis- with the specific SalI and NotI that are obtained in step (2)
The pET-22b-A-B carriers of digestion are attached reaction, obtain pET-22b-A-B-C plasmids;
(4) the pET-22b-A-B-C plasmids obtained in step (3) are transferred to competent E.coli DH5 α, extraction plasmid is simultaneously
Sequencing;
(5) the correct plasmid of sequencing in step (4) is transferred to competent E.coli DE3, carries out protein expression and purify, obtains
The estrogen receptor alpha targeting peptides.
7. the estrogen receptor alpha targeting peptides described in claim 1~2 are in preparing estrogen receptor alpha positive breast cancer drug
Application.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810043625.4A CN108358999A (en) | 2018-01-17 | 2018-01-17 | A kind of estrogen receptor targeting peptides and its preparation and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810043625.4A CN108358999A (en) | 2018-01-17 | 2018-01-17 | A kind of estrogen receptor targeting peptides and its preparation and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108358999A true CN108358999A (en) | 2018-08-03 |
Family
ID=63006232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810043625.4A Pending CN108358999A (en) | 2018-01-17 | 2018-01-17 | A kind of estrogen receptor targeting peptides and its preparation and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108358999A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1326941A (en) * | 2000-06-05 | 2001-12-19 | 上海博德基因开发有限公司 | New polypeptide-estrogenic receptor relative protein 9,13 and polynucleotide for encoding such polypeptide |
CN1403157A (en) * | 2001-08-21 | 2003-03-19 | 辉瑞产品公司 | Method for treating female sexual dysfunction and evaluating compound for treating female sexual dysfunction |
US6617114B1 (en) * | 1996-10-31 | 2003-09-09 | Karo Bio Ab | Identification of drug complementary combinatorial libraries |
US20030224390A1 (en) * | 2000-07-12 | 2003-12-04 | Karo Bio Ab | Method of identifying conformation-sensitive binding peptides and uses thereof |
WO2012087943A2 (en) * | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
CN103003294A (en) * | 2010-02-19 | 2013-03-27 | 密执安大学评议会 | Gene fusion targeted therapy |
WO2014047741A1 (en) * | 2012-09-27 | 2014-04-03 | University Of British Columbia | Peptide directed protein knockdown |
-
2018
- 2018-01-17 CN CN201810043625.4A patent/CN108358999A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617114B1 (en) * | 1996-10-31 | 2003-09-09 | Karo Bio Ab | Identification of drug complementary combinatorial libraries |
CN1326941A (en) * | 2000-06-05 | 2001-12-19 | 上海博德基因开发有限公司 | New polypeptide-estrogenic receptor relative protein 9,13 and polynucleotide for encoding such polypeptide |
US20030224390A1 (en) * | 2000-07-12 | 2003-12-04 | Karo Bio Ab | Method of identifying conformation-sensitive binding peptides and uses thereof |
CN1403157A (en) * | 2001-08-21 | 2003-03-19 | 辉瑞产品公司 | Method for treating female sexual dysfunction and evaluating compound for treating female sexual dysfunction |
CN103003294A (en) * | 2010-02-19 | 2013-03-27 | 密执安大学评议会 | Gene fusion targeted therapy |
WO2012087943A2 (en) * | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
WO2014047741A1 (en) * | 2012-09-27 | 2014-04-03 | University Of British Columbia | Peptide directed protein knockdown |
Non-Patent Citations (5)
Title |
---|
ASONA LUI等: ""Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells"", 《BMC CANCER》 * |
KATHLEEN SALAZAR-RAMÍREZ等: ""Molecular mechanisms of autophagy and its role in cancer development"", 《REV. FAC. MED.》 * |
MARIA LOMBARDI等: ""Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells"", 《J. CELL BIOL.》 * |
余元勋等: "《中国分子乳腺癌学》", 31 July 2017, 安徽科学技术出版社 * |
刘玲玲等: ""雌激素受体α型抗体的制备及临床应用研究"", 《生物技术通讯》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chiasson et al. | Soybean SAT1 (Symbiotic Ammonium Transporter 1) encodes a bHLH transcription factor involved in nodule growth and NH4+ transport | |
Shao et al. | Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma | |
Lauer-Fields et al. | Melanoma cell CD44 interaction with the α1 (IV) 1263–1277 region from basement membrane collagen is modulated by ligand glycosylation | |
Lucas et al. | A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development | |
CN108795880B (en) | Mouse hybridoma cell strain for generating human thymidine kinase 1(TK1) specific monoclonal antibody and application thereof | |
EP3323831A1 (en) | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor | |
CN111205361B (en) | Interleukin 21 protein (IL21) mutant and application thereof | |
JPH06505011A (en) | Ligand growth factor that binds to erbB-2 receptor protein and induces a cellular response | |
CN101643511A (en) | Fusion protein for inhibiting telomerase activity, preparation and application thereof | |
CN112553231A (en) | Recombinant human heat shock protein HSP90-His and expression and purification method thereof | |
CN107827970A (en) | A kind of suppression FOXM1 anti-tumor protein peptide | |
CN108358999A (en) | A kind of estrogen receptor targeting peptides and its preparation and application | |
CN106589062B (en) | Anti-tumor covalent polypeptide inhibitor targeting Grb2 protein and preparation method and application thereof | |
CN110872354B (en) | Chicken-derived monoclonal antibody and single-chain antibody of mammal cell recombinant anti-human TK1, and preparation method and application thereof | |
Screnci et al. | Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point | |
Suzuki et al. | Domain recognition of the ING1 tumor suppressor by a panel of monoclonal antibodies | |
CN114195897A (en) | PD-L1 monoclonal antibody, heavy chain and light chain variable regions, monoclonal cell strain, application and kit | |
Fan et al. | Selection of peptide ligands binding to fibroblast growth factor receptor 1 | |
CN114057879A (en) | PD-L1 monoclonal antibody, heavy chain and light chain variable regions, monoclonal cell strain, application and kit | |
Zhang et al. | Overexpression of the Interferon regulatory factor 4-binding protein in human colorectal cancer and its clinical significance | |
Salehi-Lalemarzi et al. | Cloning and stable expression of cdna coding for platelet endothelial cell adhesion molecule-1 (pecam-1, cd31) in nih-3t3 cell line | |
Mittal et al. | Mode of action of the retrogene product SNAI1P, a SNAIL homolog, in human breast cancer cells | |
Lee et al. | Expression and in vitro function of anti-PD-L1 human antibody expressed in plant | |
Kim et al. | Sumoylation of a small isoform of NFATc1 is promoted by PIAS proteins and inhibits transactivation activity | |
CN107686519A (en) | The preparation method and applications of anti-mouse MXRA7 monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180803 |
|
RJ01 | Rejection of invention patent application after publication |